January 24, 2017 (US time) – Elanco Animal Health, a division of Eli Lilly and Company (hereinafter called “Elanco”), and Aratana Therapeutics Inc. (hereinafter called “Aratana”) have announced that Galliprant® (EP4 antagonist /grapiprant/RQ-00000007/AT-001, hereinafter called “Galliprant”) is now available for the management of pain and inflammation associated with canine osteoarthritis (OA) in the USA.